Puma Biotechnology Stock Forecast, Price & News

Puma Biotechnology (NASDAQ:PBYI) Frequently Asked Questions

Is Puma Biotechnology a buy right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Puma Biotechnology in the last year. There are currently 1 sell rating, 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" Puma Biotechnology stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in PBYI, but not buy additional shares or sell existing shares.
View analyst ratings for Puma Biotechnology or view top-rated stocks.

How has Puma Biotechnology's stock been impacted by Coronavirus?

Puma Biotechnology's stock was trading at $9.27 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, PBYI shares have decreased by 67.6% and is now trading at $3.00.
View which stocks have been most impacted by COVID-19.

When is Puma Biotechnology's next earnings date?

Puma Biotechnology is scheduled to release its next quarterly earnings announcement on Thursday, February 24th 2022.
View our earnings forecast for Puma Biotechnology.

How were Puma Biotechnology's earnings last quarter?

Puma Biotechnology, Inc. (NASDAQ:PBYI) announced its earnings results on Thursday, November, 4th. The biopharmaceutical company reported ($1.09) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.31) by $0.78. The biopharmaceutical company earned $46.20 million during the quarter, compared to the consensus estimate of $53.44 million. Puma Biotechnology had a negative net margin of 19.29% and a negative trailing twelve-month return on equity of 665.45%. The company's revenue was down 9.1% on a year-over-year basis. During the same period last year, the firm earned ($0.79) EPS.
View Puma Biotechnology's earnings history.

What price target have analysts set for PBYI?

4 Wall Street analysts have issued 1-year target prices for Puma Biotechnology's stock. Their forecasts range from $6.00 to $15.00. On average, they anticipate Puma Biotechnology's share price to reach $10.00 in the next year. This suggests a possible upside of 233.3% from the stock's current price.
View analysts' price targets for Puma Biotechnology or view top-rated stocks among Wall Street analysts.

Who are Puma Biotechnology's key executives?

Puma Biotechnology's management team includes the following people:

• Alan H. Auerbach, Chairman, President, CEO & Secretary (LinkedIn Profile)
• Maximo F. Nougues, Chief Financial Officer (LinkedIn Profile)
• Jeffrey Ludwig, Chief Commercial Officer
• Mariann Ohanesian, Senior Director-Investor Relations
• Douglas Hunt, SVP-Regulatory Affairs & Medical Writing (LinkedIn Profile)

Who are some of Puma Biotechnology's key competitors?

Some companies that are related to Puma Biotechnology include Ocular Therapeutix (OCUL), Pliant Therapeutics (PLRX), Summit Therapeutics (SMMT), Calliditas Therapeutics AB (publ) (CALT), Intercept Pharmaceuticals (ICPT), Pharvaris (PHVS), Deciphera Pharmaceuticals (DCPH), Spero Therapeutics (SPRO), Verastem (VSTM), Gracell Biotechnologies (GRCL), Mersana Therapeutics (MRSN), Flexion Therapeutics (FLXN), BELLUS Health (BLU), Akebia Therapeutics (AKBA) and Rigel Pharmaceuticals (RIGL).
View all of PBYI's competitors.

What other stocks do shareholders of Puma Biotechnology own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Puma Biotechnology investors own include (MDVN) (MDVN), BioMarin Pharmaceutical (BMRN), Incyte (INCY), First Solar (FSLR), Dynavax Technologies (DVAX), United Airlines (UAL), (KITE) (KITE), Array Technologies (ARRY), Freeport-McMoRan (FCX) and (CELG).

What is Puma Biotechnology's stock symbol?

Puma Biotechnology trades on the NASDAQ under the ticker symbol "PBYI."

Who are Puma Biotechnology's major shareholders?

Puma Biotechnology's stock is owned by many different retail and institutional investors. Top institutional investors include Camber Capital Management LP (8.38%), BlackRock Inc. (7.85%), Millennium Management LLC (4.08%), Renaissance Technologies LLC (3.99%), AIGH Capital Management LLC (2.11%) and Goldman Sachs Group Inc. (1.98%). Company insiders that own Puma Biotechnology stock include Alan H Auerbach, Ann Calby Miller, Douglas M Hunt, Jay M Moyes, Langley Steinert, Maximo F Nougues, Richard Paul Bryce and Troy Edward Wilson.
View institutional ownership trends for Puma Biotechnology.

Which institutional investors are selling Puma Biotechnology stock?

PBYI stock was sold by a variety of institutional investors in the last quarter, including AIGH Capital Management LLC, Citigroup Inc., Two Sigma Investments LP, Cubist Systematic Strategies LLC, Geode Capital Management LLC, Deutsche Bank AG, Citadel Advisors LLC, and Panagora Asset Management Inc.. Company insiders that have sold Puma Biotechnology company stock in the last year include Alan H Auerbach, Ann Calby Miller, Douglas M Hunt, Langley Steinert, Maximo F Nougues, and Richard Paul Bryce.
View insider buying and selling activity for Puma Biotechnology or view top insider-selling stocks.

Which institutional investors are buying Puma Biotechnology stock?

PBYI stock was acquired by a variety of institutional investors in the last quarter, including Millennium Management LLC, Camber Capital Management LP, Goldman Sachs Group Inc., Eversept Partners LP, Russell Investments Group Ltd., BlackRock Inc., Los Angeles Capital Management LLC, and GSA Capital Partners LLP.
View insider buying and selling activity for Puma Biotechnology or or view top insider-buying stocks.

How do I buy shares of Puma Biotechnology?

Shares of PBYI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Puma Biotechnology's stock price today?

One share of PBYI stock can currently be purchased for approximately $3.00.

How much money does Puma Biotechnology make?

Puma Biotechnology has a market capitalization of $122.66 million and generates $225.10 million in revenue each year. The biopharmaceutical company earns $-59.99 million in net income (profit) each year or ($1.20) on an earnings per share basis.

How many employees does Puma Biotechnology have?

Puma Biotechnology employs 267 workers across the globe.

What is Puma Biotechnology's official website?

The official website for Puma Biotechnology is www.pumabiotechnology.com.

Where are Puma Biotechnology's headquarters?

Puma Biotechnology is headquartered at 10880 WILSHIRE BOULEVARD SUITE 2150, LOS ANGELES CA, 90024.

How can I contact Puma Biotechnology?

Puma Biotechnology's mailing address is 10880 WILSHIRE BOULEVARD SUITE 2150, LOS ANGELES CA, 90024. The biopharmaceutical company can be reached via phone at (424) 248-6500, via email at [email protected], or via fax at 424-248-6501.